

Letter to the Editor

Markus Glaß, Laura Michaela Schian, Danny Misiak, Claudia Misiak, Simon Müller, Alexander Rausch, Katharina Angermann, Mariann Hoyer, Ramona Zabel, Ramyatha Battula, Astrid Kehlen, Beate Möbius, Jessica Weickert, Stefan Hüttelmaier and Matthias Karrasch*

It did not stop there: rapid substitution of circulating SARS-CoV-2 variant of concern B.1.1.7 (Alpha) by variant of concern B.1.617.2 (Delta) and further evolution of different Delta sublineages in Southern Saxony-Anhalt in late summer 2021

<https://doi.org/10.1515/labmed-2021-0168>

Received November 10, 2021; accepted November 26, 2021;

published online December 14, 2021

Keywords: SARS-CoV-2; surveillance; whole genome sequencing (WGS).

To the Editor,

In a recently published manuscript in the *Journal of Laboratory Medicine* [1], we reported about the establishment of a regional SARS-CoV-2 surveillance program using whole genome sequencing (WGS) of SARS-CoV-2 isolates. Specimens were collected over a period of 5 months (January to May 2021) from patients suffering from COVID-19 and from outpatients without any

Stefan Hüttelmaier and Matthias Karrasch contributed equally to this work.

*Corresponding author: **Matthias Karrasch**, MD, Department of Laboratory Medicine, Unit III, Halle University Hospital, Halle (Saale), Germany, E-mail: matthias.karrasch@uk-halle.de

Markus Glaß, Laura Michaela Schian, Danny Misiak, Claudia Misiak, Simon Müller, Alexander Rausch and Stefan Hüttelmaier, Institute of Molecular Medicine, Section for Molecular Cell Biology, Charles Tanford Protein Centre, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

Katharina Angermann, A&A Praxis für Laboratoriumsmedizin und Med. Mikrobiologie, Halle (Saale), Germany

Mariann Hoyer and Ramona Zabel, Amedes MVZ für Laboratoriumsdiagnostik und Mikrobiologie Halle/Leipzig GmbH, Halle (Saale), Germany

Ramyatha Battula, Astrid Kehlen, Beate Möbius and Jessica Weickert, Department of Laboratory Medicine, Unit III, Molecular Diagnostic Section, Halle University Hospital, Halle (Saale), Germany

clinical signs or symptoms. Sequence libraries were constructed from total RNA extracts using the Illumina COVIDSeq Test kit (Illumina, San Diego, US). During this time frame, the majority of the obtained sequences (252/364=69%) were assigned to the SARS-CoV-2 variant of concern (VOC) Alpha (B.1.1.7), and only very few other VOCs were found in our cohort [Beta (B.1.351, n=2); Delta (B.1.617.2, n=1)]. This situation rapidly changed throughout the summer months of June to September 2021, in which VOC Delta (B.1.617.2 and sublineages AY.xx) rapidly became the dominant SARS-CoV-2 lineage in our study population within only one month (see Figure 1). In the months August and September 2021, a multitude of further Delta sublineages emerged (Figure 1). This spread of VOC Delta could also be observed when comparing SARS-CoV-2 genome sequences from the entire country of Germany collected in the same time period, and submitted to GISAID (gisaid.org) [2]. A similar development was reported from other European countries [3, 4]. We have created interactive websites providing up-to-date SARS-CoV-2 lineage distribution from our local area. All unfolding data determined by our surveillance program are accessible via the URL https://ngs-info.medizin.uni-halle.de/shiny/SARS_CoV2/SARS_CoV2.html. As already mentioned in our previously published manuscript [1], this fast changing situation further fosters the need for an established SARS-CoV-2 testing by WGS as an important surveillance tool for early detection of upcoming new lineages of concern [4, 5].

While in June all sequenced SARS-CoV-2 genomes from the study population were classified as B.1.1.7 (VOC Alpha), from July on only B.1.617.2 and its sublineages AY.xx (VOC Delta) were found.




Figure 1: SARS-CoV-2 lineage distribution from June to September 2021.

Acknowledgments: The authors would like to thank Anke Cachay, Monique Dreher, Anastassia Teuber, Gabriele Unger and Nancy Wurg (Department of Laboratory Medicine, Unit III, Molecular Diagnostic Section, Halle University Hospital) for specimen handling, SARS-CoV-2 RNA isolation/inactivation and SNP-PCR, as well as Michael Böttcher and Ghanem El Kassem (Charles Tanford Protein Centre, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany) for cooperation with the Illumina MiniSeq. We further acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's hCov19 Database.

Research funding: None declared.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors state no conflict of interest.

Informed consent: Informed consent was obtained from all individuals included in this study.

Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

- Glaß M, Misiak D, Misiak C, Müller S, Rausch A, Angermann K, et al. Fast forward evolution in real time: the Rapid spread of SARS-CoV-2 variant of concern lineage B.1.1.7. In Saxony-Anhalt over a period of 5 months. *J Lab Med* 2022;46:71–5.
- Calvignac-Spencer S, Budt M, Huska M, Richard H, Leipold L, Grabenhenrich L, et al. Rise and fall of SARS-CoV-2 lineage A.27 in Germany. *Viruses* 2021;13:1491.
- Mishra S, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. *EClinicalMedicine* 2021;39: 101064.
- Molenkamp R, Fanoy E, Derickx L, de Groot T, Jonges M, Leenstra T, et al. Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, The Netherlands, June to July 2021. *Euro Surveill* 2021;26:2100921.
- Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Klapper P, Wigglesworth M. High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. *EBioMedicine* 2021;70:103540.